Deutsche Bank raised its price target on Biogen (NASDAQ: BIIB) to $319.00 (from $315.00) while maintaining a Buy rating ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Analyst Comments Analyst EPS View Analyst PT Change

Biogen (BIIB) PT Raised to $328 at BMO Capital; '2Q17 Couldn’t Have Been Better Operationally'July 26, 2017 10:53 AM Biogen (BIIB) PT Raised to $285 at UBS Following Strong 2Q July 26, 2017 8:44 AM Biogen (BIIB) PT Raised to $311 at Morgan StanleyJuly 26, 2017 7:58 AM Goldman Sachs Upgrades Biogen (BIIB) to BuyJuly 26, 2017 5:07 AM Biogen (BIIB) Tops Q2 EPS by 59c, Sales Beat; Raises OutlookJuly 25, 2017 6:31 AM Biogen Reports Record Quarterly Revenues of $3.1 Billion, Raises Full Year Revenue GuidanceJuly 25, 2017 6:30 AM